Cargando…
Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas
SIMPLE SUMMARY: Epstein-Barr virus (EBV) is the first-discovered and important human tumor virus. It infects more than 90% of human population and induces various lymphomas. Development of specific targeted therapies is very critical for treatment of EBV-induced lymphomas, but it remains a great cha...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564798/ https://www.ncbi.nlm.nih.gov/pubmed/32916819 http://dx.doi.org/10.3390/cancers12092565 |
_version_ | 1783595796366622720 |
---|---|
author | Pei, Yonggang Wong, Josiah H. Y. Robertson, Erle S. |
author_facet | Pei, Yonggang Wong, Josiah H. Y. Robertson, Erle S. |
author_sort | Pei, Yonggang |
collection | PubMed |
description | SIMPLE SUMMARY: Epstein-Barr virus (EBV) is the first-discovered and important human tumor virus. It infects more than 90% of human population and induces various lymphomas. Development of specific targeted therapies is very critical for treatment of EBV-induced lymphomas, but it remains a great challenge. In this review, we introduced the current progress of EBV-specific therapies and the promising approaches that can be developed as novel targeted therapies, which involve protective or therapeutic strategies to target these lymphomas on different levels. This work will provide new insights into the development of new targeted therapies against EBV-associated lymphomas. ABSTRACT: The Epstein-Barr virus (EBV) is the first human tumor virus identified that can transform quiescent B lymphocytes into lymphoblastoid cell lines (LCLs) in vitro. EBV can establish asymptomatic life-long persistence and is associated with multiple human malignancies, including non-Hodgkin lymphoma and Hodgkin lymphoma, as well as infectious mononucleosis. Although EBV-associated lymphomagenesis has been investigated for over 50 years, viral-mediated transformation is not completely understood, and the development of EBV-specific therapeutic strategies to treat the associated cancers is still a major challenge. However, the rapid development of several novel therapies offers exciting possibilities to target EBV-induced lymphomas. This review highlights targeted therapies with potential for treating EBV-associated lymphomas, including small molecule inhibitors, immunotherapy, cell therapy, preventative and therapeutic vaccines, and other potent approaches, which are novel strategies for controlling, preventing, and treating these viral-induced malignances. |
format | Online Article Text |
id | pubmed-7564798 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75647982020-10-26 Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas Pei, Yonggang Wong, Josiah H. Y. Robertson, Erle S. Cancers (Basel) Review SIMPLE SUMMARY: Epstein-Barr virus (EBV) is the first-discovered and important human tumor virus. It infects more than 90% of human population and induces various lymphomas. Development of specific targeted therapies is very critical for treatment of EBV-induced lymphomas, but it remains a great challenge. In this review, we introduced the current progress of EBV-specific therapies and the promising approaches that can be developed as novel targeted therapies, which involve protective or therapeutic strategies to target these lymphomas on different levels. This work will provide new insights into the development of new targeted therapies against EBV-associated lymphomas. ABSTRACT: The Epstein-Barr virus (EBV) is the first human tumor virus identified that can transform quiescent B lymphocytes into lymphoblastoid cell lines (LCLs) in vitro. EBV can establish asymptomatic life-long persistence and is associated with multiple human malignancies, including non-Hodgkin lymphoma and Hodgkin lymphoma, as well as infectious mononucleosis. Although EBV-associated lymphomagenesis has been investigated for over 50 years, viral-mediated transformation is not completely understood, and the development of EBV-specific therapeutic strategies to treat the associated cancers is still a major challenge. However, the rapid development of several novel therapies offers exciting possibilities to target EBV-induced lymphomas. This review highlights targeted therapies with potential for treating EBV-associated lymphomas, including small molecule inhibitors, immunotherapy, cell therapy, preventative and therapeutic vaccines, and other potent approaches, which are novel strategies for controlling, preventing, and treating these viral-induced malignances. MDPI 2020-09-09 /pmc/articles/PMC7564798/ /pubmed/32916819 http://dx.doi.org/10.3390/cancers12092565 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Pei, Yonggang Wong, Josiah H. Y. Robertson, Erle S. Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas |
title | Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas |
title_full | Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas |
title_fullStr | Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas |
title_full_unstemmed | Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas |
title_short | Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas |
title_sort | targeted therapies for epstein-barr virus-associated lymphomas |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564798/ https://www.ncbi.nlm.nih.gov/pubmed/32916819 http://dx.doi.org/10.3390/cancers12092565 |
work_keys_str_mv | AT peiyonggang targetedtherapiesforepsteinbarrvirusassociatedlymphomas AT wongjosiahhy targetedtherapiesforepsteinbarrvirusassociatedlymphomas AT robertsonerles targetedtherapiesforepsteinbarrvirusassociatedlymphomas |